Original Article

Phosphorylated c-Src is a novel predictor for recurrence in cervical squamous cell cancer patients

Teng Hou*, Juan Xiao*, Huiting Zhang, Haifeng Gu, Yanling Feng, Jundong Li

State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, GD 510060, China. *Equal contributors.

Received April 8, 2013; Accepted April 19, 2013; Epub May 15, 2013; Published June 1, 2013

Abstract: Aims: The molecular mechanisms of the tumorigenesis and recurrence of cervical cancer are poorly understood. The objective of this study was to analyze the expression of phosphorylated c-Src (phospho-c-Src) and its clinical significance in human cervical cancer. Methods: The expression of phospho-c-Src was determined by immunohistochemistry in a total of 127 cervical specimens including 20 normal cervix tissues, 20 cases of carcinoma in situ of cervix (CIS), and 87 cases of cervical squamous cell carcinoma (CSCC). Results: The expression of phospho-Src in normal cervix, CIS, and CSCC increased gradually in ascending order (p=0.026). In addition, the expression of phospho-Src was correlated with overall (p=0.037) and recurrence (p=0.001) survival of cervical cancer. In multivariate Cox regression analysis, phospho-Src expression was an independent prognosis factor for recurrence-free survival (p=0.004). Conclusion: Our present study suggests that Src signaling may play essential role in cervical cancer progression. Phospho-Src expression may be considered as a prognostic marker to predict recurrence in CSCC.

Keywords: Phospho-Src, cervical squamous cell carcinoma, prognosis, recurrence

Introduction

Cervical squamous cell carcinoma (CSCC) is one of the most frequent malignant tumors in the female reproductive organs and accounts for 90% of cervical cancers [1]. Early stage CSCC could be cured on a rate of more than 80% with either radical resection or radiation [2], yet recurrence remains probably one of the most difficult challenges in the treatment of CSCC. The reported recurrence rates of stage I–II cervical cancer after radical hysterectomy or radiotherapy are between 10 and 18% [3]. Generally, the clinical outcome of recurrent cervical cancer patients is poor, with the 5-year survival rates ranging from 3.2 and 22.3% [4-6]. Although extensive researches have been done, there is a lack of therapeutic targets that can improve the treatment outcomes of recurrent cervical cancer.

Src belongs to a family of non-receptor intracellular tyrosine kinase proteins. It is consisted of seven parts including SH1-SH4 domain, unique domain, SH2–SH3 linker, and a c-terminal negative regulatory region [7]. Recent reports showed that Src kinase exert multifaceted functions by interacting with tyrosine kinase receptors, such as VEGF and EGFR receptor, or via a variety of intracellular signaling pathways involved in tumor cell growth, cell motility, angiogenesis, and invasion during tumor development [8]. Overexpression of Src has been associated with enhanced cancer cell growth, while depletion of Src by antisense oligonucleotides results in reduced cell division [9]. Indeed, tumor cells expressing higher levels of activated Src are associated with tumor invasiveness and metastasis both in vivo and in vitro models [10]. In contrast, inhibition of Src kinase significantly repressed the invasive and metastatic behavior of cancer cells [11]. Moreover, increased expression of Src kinase has been associated with the development and progression of a number of human malignancies, including pancreatic, colon, ovarian and breast carcinoma [7, 12]. Stabile et al. demonstrated that the expression of phospho-c-Src is correlated with poor differentiation and lymph node metastases in patients with head and
Prognostic role of phospho-c-Src in cervical cancer


Campbell et al. suggested that nuclear localization of phosphorylated c-Src is associated with improved clinical outcome in patients with ER-positive breast cancer [14]. Wilson et al. shown that c-Src activation is correlatd with tumour grade, tumor cell proliferation, and HER2 expression in ductal carcinoma in situ [15]. Furthermore, elevated Src kinase activity contributes to attenuated response to endo-

crine therapy in breast cancer [16]. These stud-

ies together indicate the important role of Src kinase in tumor progression and potential ther-

apeutic sensitivity of human malignancies.

Although increased phospho-Src expression has been found in cervical cell lines and clinical cervical cancer tissues, and downregulation of phospho-Src led to cell growth inhibition [17], elucidation of the biological functions of Src kinase expression on the tumor progression and prognosis of cervical cancer remains incomplete. In the present study, we investigat-
ed the expression of phospho-Src in histologi-
cal sections of 87 cases of CSCC, 20 cases of

carcinoma in situ of cervix, and 20 cases of

normal cervix tissues using immunohistochemi-

technique. We report for the first time the cor-

relation of phospho-Src expression and poor

prognosis in patients with CSCC. Multivariate

analysis suggested that phospho-Src expres-
sion was an independent prognostic marker for

recurrence in patients with CSCC. Our data

strongly suggest that Src family kinase may

play essential role in cervical cancer progres-
sion, and that phospho-Src may be a valuable

marker for predicting postoperative recurrence

in CSCC patients.

Material and methods

Patients and tissue specimens

A total of 127 paraffin-embedded samples were obtained at Sun Yat-Sen University Cancer Center between Jan 2005 and Jan 2006. The samples were composed of 20 normal cervical tissues, 20 CIS, and 87 CSCC. For the use of these clinical materials for research purposes, prior patient consent and approval from the Institutional Research Ethics Committee were
obtained. None of the patients had received chemotherapy or radiotherapy before surgery. The clinical characteristics of the 87 patients with CSCC are listed in Table 1. The disease stage of each patient was classified or reclassified according to the International Federation of Gynecology and Obstetrics criteria as follows: 30 were allocated to stage IB1, 30 to stage IB2, 13 to stage IIA1, 8 to stage IIA2, and 6 to stage IIB. The median age of the patients was 42.9 years (range 26–64 years).

Immunohistochemistry

Immunohistochemistry was done to study phospho-Src expression in 87 human CSCC, 20 CIS, and 20 normal cervical tissues. In brief, paraffin-embedded specimens were cut into 4 μm sections and mounted on poly-L-lysine-coated slides. The sections were baked at 65°C for 30 minutes, then deparaffinized in xylene and rehydrated. Antigen retrieval was performed by submerging the sections into a 10 μmol/L citrate buffer solution (pH 6.0) for 10 minutes in a microwave oven. The slides were then treated with 3% hydrogen peroxide in methanol to quench the endogenous peroxidase activity, followed by incubation with 1% fish skin gelatin to block the nonspecific staining. Tissue sections were incubated overnight with polyclonal rabbit antibody against phospho-Src (Tyr416) (Cell Signaling Technology, USA; 1:60). After washing, the sections were incubated with prediluted anti-rabbit secondary antibody (Zymed, San Francisco, CA), followed by further incubation with 3,3-diaminobenzidine tetrahydrochloride (DAB). Finally, the slides were counterstained with 10% Mayer’s hematoxylin and mounted in Crystal Mount.

The degree of immunostaining of formalin-fixed, paraffin-embedded sections was reviewed and scored by two independent observers. The proportion of the stained cells and the extent of the staining were used as criteria of evaluation. The intensity of membranous and cytoplasmic staining was graded semi-quantitatively into four levels: 0 (no staining); 1 (weak staining = light yellow); 2 (moderate staining = yellow brown) and 3 (strong staining = brown); and the percentage of stained cells was scored as: 0, negative; 1, 10% or less; 2, 11% to 50%; 3, 51% to 80%; or 4, 80% or more positive cells. A final score was defined by multiplying the percentage of positive cells by the intensity. The final score was defined as negative for score 0-4 and as positive for scores of 6–12.

Statistical analysis

All statistical analyses were carried out using the SPSS 16.0 statistical software. Chi-square test and Fisher’s exact was used to analyze the relationship between phospho-Src expression and clinicopathologic characteristics. Survival curves were plotted by the Kaplan-Meier method and compared by the log-rank test. Survival data was analyzed using univariate and multivariate Cox regression analyses. P<0.05 in all cases was considered statistically significant.

Results

Expression of phospho-Src in CSCC, CIS, and normal cervix

To investigate the potential roles of Src signaling in the tumorigenesis of CSCC, we examined the expression of phospho-Src in 87 paraffin-embedded CSCC, 20 CIS, and 40 normal cervical tissues by immunohistochemistry. The representative immunostaining of phospho-Src in normal cervix tissues (Figure 1A and 1B), CIS (Figure 1C and 1D), and CSCC (Figure 1E–H) were shown in Figure 1. Normal cervical tissue showed positive phospho-Src in 0 (0%) cases, CIS present 1 (5%), and CSCC positively stained 18 (20.7%) cases, respectively (Table 1). The expression of phospho-Src increases as CSCC progresses to more advanced stages (P=0.026). Taken together, these results suggested that phospho-Src was correlated with the tumorigenesis of CSCC.

Expression of phospho-Src with the clinical features of CSCC

We next examined the correlation between the expression of phospho-Src and the clinicopathological characteristics of CSCC. As shown in Table 2, phospho-Src expression strongly cor-
Prognostic role of phospho-c-Src in cervical cancer

A

B

Figure 2. Kaplan-Meier analysis of overall survival (A) and recurrence-free survival (B) in relation to phospho-Src expression in 87 cervical squamous cell cancer (CSCC) patients.

Table 2. Expression of phospho-Src expression in CSCC patients according to clinicopathologic characteristics

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>NO.</th>
<th>phospho-Src</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Positive N (%)</td>
<td>Negative N (%)</td>
</tr>
<tr>
<td>Age (y)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤40</td>
<td>40</td>
<td>9 (22.5)</td>
<td>31 (77.5)</td>
</tr>
<tr>
<td>&gt;40</td>
<td>47</td>
<td>9 (19.1)</td>
<td>38 (80.9)</td>
</tr>
<tr>
<td>FIGO Stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IB1</td>
<td>30</td>
<td>8 (26.7)</td>
<td>22 (73.3)</td>
</tr>
<tr>
<td>&gt;IB1</td>
<td>57</td>
<td>10 (17.5)</td>
<td>47 (82.5)</td>
</tr>
<tr>
<td>Differentiation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade 1/2</td>
<td>39</td>
<td>7 (17.9)</td>
<td>32 (82.1)</td>
</tr>
<tr>
<td>Grade 3</td>
<td>48</td>
<td>11 (22.9)</td>
<td>37 (77.1)</td>
</tr>
<tr>
<td>LN Metastasis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-</td>
<td>79</td>
<td>17 (21.5)</td>
<td>62 (78.5)</td>
</tr>
<tr>
<td>+</td>
<td>8</td>
<td>1 (12.5)</td>
<td>7 (87.5)</td>
</tr>
<tr>
<td>Recurrence</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-</td>
<td>79</td>
<td>13 (16.5)</td>
<td>66 (83.5)</td>
</tr>
<tr>
<td>+</td>
<td>8</td>
<td>5 (62.5)</td>
<td>3 (37.5)</td>
</tr>
</tbody>
</table>

Discussion

Currently, the exact molecular mechanisms of the progression and recurrence of cervical cancer are unclear, and there is lack of biomarkers to predict cervical cancer recurrence. In this study, we observed that the expression of phospho-Src in normal cervix, CIS, and CSCC increased gradually in ascending order. We also demonstrated that expression of phospho-Src was correlated with overall survival and recurrence of cervical cancer. Patients with high phospho-Src expression had shorter overall and recurrence-free survival time, and patients with low phospho-Src expression had longer survival time. Multivariate analysis indicated that phospho-Src expression was an independent prognosis factor for recurrence-free survival. Our present study reveals that phospho-Src may play essential role in cervical cancer progression, and that it may represent a valuable marker to predict recurrence in CSCC.

It has been demonstrated previously that Src family kinases are implicated in squamous epithelial differentiation and in cancer develop-
Table 3. Multivariate Cox regression analysis of overall survival (OS) and Recurrence-free survival (RFS) in patients with CSCC

<table>
<thead>
<tr>
<th>Prognostic variables</th>
<th>OS Hazard ratio (95% CI)</th>
<th>P</th>
<th>RFS Hazard ratio (95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (&gt;40 vs ≤40)</td>
<td>1.983 (0.469-8.399)</td>
<td>0.352</td>
<td>4.344 (0.820-23.019)</td>
<td>0.084</td>
</tr>
<tr>
<td>FIGO Stage (&gt;IB1 vs IB1)</td>
<td>1.006 (0.239-4.239)</td>
<td>0.993</td>
<td>2.213 (0.435-11.266)</td>
<td>0.339</td>
</tr>
<tr>
<td>Differentiation (Grade 3 vs 1/2)</td>
<td>3.019 (0.622-14.659)</td>
<td>0.170</td>
<td>1.526 (0.355-6.572)</td>
<td>0.570</td>
</tr>
<tr>
<td>LN Metastasis (+ vs -)</td>
<td>1.348 (0.154-11.834)</td>
<td>0.787</td>
<td>1.594 (0.187-13.582)</td>
<td>0.670</td>
</tr>
<tr>
<td>phospho-Src (+ vs -)</td>
<td>3.714 (0.991-13.912)</td>
<td>0.052</td>
<td>8.636 (2.013-37.046)</td>
<td>0.004</td>
</tr>
</tbody>
</table>

ment and progression [18]. Cancer-associated c-Src can suppress cell attachment and motility by affecting the process of actin-filament or integrin–actin cytoskeleton assembly [19]. In addition, activated Src/focal adhesion kinase complex promotes tumor cell survival and invasion via activation of the PI3K/Akt pathway [20]. Moreover, overexpression of c-Src can enhance epidermal growth factor-induced DNA synthesis in cancer cells, which in turn leads to tumor cell proliferation and migration [21]. Furthermore, Src kinases can induce tumor angiogenesis either by regulating the gene expression of angiogenic growth related factors/cytokines or by cooperating with angiogenic growth factor receptors [22, 23]. These studies indicated that Src family kinases may contribute to the development and progression of cancer.

Src protein has been reported to be highly expressed in several cancers including head and neck cancers, malignant skin cancers, thyroid papillary carcinomas, and pancreatic carcinomas [24-27]. In several precancerous lesions, elevated Src kinase activity is also detected [28, 29]. To investigate whether Src kinases are correlated to the progression of cervical cancer, we performed immunohistochemical studies to characterize the expression of phospho-Src in normal cervical tissues, carcinoma in situ of cervix, and CSCC specimens. We found that the expression of phospho-Src increases as CSCC progresses to more advanced stages, which is in agreement with previous studies. The stepwise and remarkable increase in the phospho-Src expression from normal cervical tissues through CIS to cervical cancer implicated that Src signaling may play a critical role in the progression of cervical carcinoma.

Recent studies have also correlated Src kinase overexpression with tumor progression and clinical prognosis. Ben-Izhak et al. demonstrated an inverse correlation between phospho-Src kinase expression and 5-year overall survival rate in patients with tongue cancer [30]. Zhang et al. suggested that patients with positive c-Src expression exhibited significantly worse progression-free and disease-specific survival in breast cancer [31]. Chatzizacharias et al. revealed that Src expression correlated significantly with the tumor stage and overall survival in patients with pancreatic ductal adenocarcinoma [32]. In this study, we analyzed the correlation between phospho-Src expression and prognosis in CSCC patients, and we found that high expression of phospho-Src is associated with poor overall survival, which is in agreement with most previous studies. In contrast to our findings, Campbell et al. reported that phospho-Src kinase in the nucleus is associated with favorable outcome in ER-positive breast cancer patients [14]. As nuclear expression of phospho-Src was rarely observed either in our study or in other cancers, their finding may be associated with ER-positive breast cancer cohort [14].

It is particularly noteworthy that phospho-Src overexpression has been found, in our study, to be associated with shorter recurrence-free survival. Our finding is supported by Wilson [15], who suggested that high levels of activated Src may indicate a greater risk of tumor recurrence. Cheng et al. also described that Src expression is significantly correlated with the progression and recurrence in patients with oral squamous cell carcinoma [17]. Similarly to these studies, de Heer et al. discovered that high levels of FAK and Src were associated with shorter time to recurrence of colorectal cancer [33]. Redmond et al. described that Src-1 was a strong independent predictor of shorter disease-free survival in breast cancer [34]. Together these findings underline an important role of phos-
Prognostic role of phospho-c-Src in cervical cancer

In conclusion, this study showed a significantly higher phospho-Src expression in CSCC than in CIS and normal cervical specimens. We also found a significant correlation of phospho-Src expression and overall survival. Moreover, CSCC patients with phospho-Src expression are more likely to have recurrent disease than those without phospho-Src expression. These results indicate that phospho-Src can be used as a biomarker for prediction of the progression and recurrence of patients with CSCC.

Funding source

This work was supported by grant from the Guangdong Medical Science Foundation (2012B031800385).

Address correspondence to: Dr. Jundong Li, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, GD 510060, China. Tel: 0086-1871-8908-165; Fax: 8600-20-8734-3014; E-mail: ljjd@sysucc.org.cn; 1aiyan@163.com

References

Prognostic role of phospho-c-Src in cervical cancer


